With recent approval of the first dendritic cell (DC) vaccine for patient use, many other DC vaccine approaches are now being tested in clinical trials. Many of these DC vaccines employ tumor cell lysates (TL) generated from cells cultured in atmospheric oxygen ($20% O 2 ) that greatly exceeds levels found in tumors in situ. In this study, we tested the hypothesis that TLs generated from tumor cells cultured under physiologic oxygen ($5% O 2 ) would be more effective as a source for DC antigens. Gene expression patterns in primary glioma cultures established at 5% O 2 more closely paralleled patient tumors in situ and known immunogenic antigens were more highly expressed. DCs treated with TLs generated from primary tumor cells maintained in 5% O 2 took up and presented antigens to CD8 T cells more efficiently. Moreover, CD8 T cells primed in this manner exhibited superior tumoricidal activity against target cells cultured in either atmospheric 20% O 2 or physiologic 5% O 2 . Together, these results establish a simple method to greatly improve the effectiveness of DC vaccines in stimulating the production of tumoricidal T cells, with broad implications for many of the DC-based cancer vaccines being developed for clinical application. Cancer Res; 71(21); 1-7. Ó2011 AACR.
Introduction
Therapeutic vaccination utilizing dendritic cells (DC) pulsed with tumor-associated antigens is a promising approach for cancer immunotherapy (1) . The U.S. Food and Drug Administration recently approved a peptide-pulsed DC vaccine for the treatment of prostate cancers resistant to hormone ablation (2, 3) . Tumor cells are frequently used as a source of antigen for DC-based vaccines. There are 385 clinical trials currently registered that utilize tumor cells as the source of vaccine antigen (4) . Vaccines using tumor cells and tumor cell lysates (TL) have several advantages including targeting multiple, patient-specific tumor antigens. Vaccination with TLpulsed DCs has shown encouraging results in early-stage clinical trials in numerous malignancies, but there is clearly a need for additional improvement (5) .
It remains unclear how tissue culture might affect antitumor immune responses evoked by tumor cell vaccines. Primary human glioma cells cultured in serum-containing media were genetically and phenotypically different from the primary tumor; culture of the same cells in serum-free conditions more closely reflected the primary tumor and enriched for a tumor stem cell phenotype (6) . Moreover, in a murine model, glioma cell lysates generated in serum-free conditions were more effective than those derived from serum-containing media when employed for TL-pulsed DC vaccines (7) . Traditionally, tumor cell vaccines are derived from cultures maintained at atmospheric oxygen ($20.95%; hereafter 20% O 2 ), far from the average oxygen tension of less than 6% O 2 (range, 0.1%-10%) measured in glioblastoma in situ (8) . Lowering oxygen causes alterations in gene expression, cell metabolism, proliferation, survival (9) (10) (11) (12) , and increases the expression of tumor stem cell markers CD133, Nestin, and SOX2 (13) (14) (15) . We previously showed that glioma and breast carcinoma TL vaccines derived at 5% O 2 had superior therapeutic efficacy relative to 20% O 2 in murine models. However, this previous study did not address DC vaccines and it remained uncertain if the results would translate to stimulating human leukocytes using primary human tumors, which are often heterogeneous and unpredictable. We therefore investigated the mechanisms by which oxygen may change the immunogenicity of serum-free glioma cultures derived from glioblastoma patient surgical resections.
Materials and Methods

Glioma cell culture and lysates
Surgically resected glioblastomas (Supplementary Table S1 ) were enzymatically dissociated and cultured in neural stem cell media for all experiments (16); tumors were not cultured in serum. Unless noted, all tumors were initially grown in 20% O 2 then subsequently moved to 5% O 2 for a minimum of 30 days prior to experiments as described previously (17) . About 5% O 2 was maintained by regulated nitrogen injection into a ThermoScientific Forma Series II incubator. Cultures were maintained in the indicated oxygen tension uninterrupted for at least 48 hours prior to use. To generate TLs, cells were pelleted, washed with PBS, then killed by 5 freeze thaw cycles, and complete lysis was confirmed by trypan blue exclusion.
Microarray
Total RNA was isolated from snap-frozen tissue at resection, or cultured cells from the primary tumor at grown at 5% or 20% O 2 . Expression levels of 18,401 genes were analyzed using a Whole-Genome Gene Expression DASL assay (Illumina). For detailed methods, see Supplementary Material.
Quantitative real-time PCR
Extracted RNA was analyzed by real-time PCR using SYBR Green one step PCR master mix (Qiagen). The following conditions were used for PCR in an ABI PRISM 7500 thermocycler: 95 C for 15 minutes; 94 C for 30 seconds, 55 C for 30 seconds, 68 C for 30 seconds in a total of 40 cycles; 72 C for 10 minutes; and 10 C until collected. Relative quantification of gene expression was calculated and normalized to glyceraldehyde 3 phosphate dehydrogenase expression levels using the 2 ÀDDC t ð Þ method (18) . Primers are listed in Supplementary  Table S2 .
Flow cytometry
A total of 5 Â 10 5 cells were stained with the following antibodies: anti-CD133/2 (clone 293C3; Miltenyi), EphA2 (clone 371805), SOX2 (clone 245610), Nestin (clone 196909), HER-2/neu (clone 191924; R&D Systems), and IL13Ra2 (clone B-D13; Santa Cruz Biotechnology). Following 3 washes, CD133/2 was stained with a secondary antimouse-647; IL13Ra2 and EphA2 were stained with secondary anti-mouse-PE along with their respective isotype control and analyzed using a FACSCanto II. For DC phenotyping, 5 Â 10 5 DCs were stained with CD80-FITC (clone L307.4), CD86-PE (clone IT2.2), CD83-PE (clone HB15E), HLA-DR-APC (clone G46-6), and HLA-ABC-FITC (clone W6132; BD Biosciences), incubated at 4 C for 30 minutes, washed, fixed, then analyzed on a FACSCalibur. Intracellular staining was done according to the manufacturer's protocol (BD Biosciences) using 2 mmol/L GolgiStop for 4 hours prior to staining.
TL-pulsed DCs and DC uptake assay
Monocytes were purified using CD14 magnetic beads (Miltenyi Biotech) from the peripheral blood of healthy HLA-A2 þ donors (Supplementary Table S3 ), plated at a concentration of 5 Â 10 5 in 24-well plates and matured as previously described (19) . On day 6, DCs were pulsed with whole TLs derived in either 5% or 20% O 2 containing 100 mg of protein and matured prior to experiments. To assess TL uptake, tumor cells were labeled with 10 uM carboxyfluorescein succinimidyl ester (CFSE), lysed, and pulsed onto immature DCs harvested at day 6 of culture. Twenty-four hours later later, DCs were analyzed by flow cytometry.
Cytotoxic T lymphocyte assays
A total of 1 Â 10 6 HLA-A2 þ peripheral blood mononuclear cells (PBMC) from normal donors were added to lysate-pulsed DCs with 50 IU IL-2 and incubated for 7 days. For restimulation, a second set of pulsed DCs was added to the coculture for 4 days. On day 11, PBMCs were cocultured with 2 Â 10 4 CFSElabeled HLA-A2 þ glioma cells cultured in 20% O 2 for 6 hours, then analyzed by flow cytometry to determine cytotoxicity as described (20) . For the blocking assay, 1.25 mg anti-HLA-ABC (clone G46-2.6) was added to target cells for 25 minutes before washing and adding PBMCs. A competition cytotoxic T lymphocyte (CTL) assay was also conducted whereby target cells were precultured in 2 oxygen levels and pooled as follows: 1.5 Â 10 4 glioma cells cultured in 5% O 2 were stained with 10 uM/mL of CellTrace Violet (Invitrogen) and added to 1.5 Â 10 4 glioma cells cultured in 20% O 2 stained with 10 uM/mL carboxyfluorescein succinimidyl ester (CFSE). Pooled target cells were cocultured with PBMCs in 20% O 2 for 6 hours, then analyzed by flow cytometry whereby the targets were distinguished via violet or CFSE.
CMV assay
A total of 5 Â 10 5 HLA-A2 þ immature DCs were pulsed with whole TLs derived in 5% or 20% O 2 TLs containing 100 mg of protein with or without addition of 10 mg of pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] (NLVPMVATV) and matured as described above. Following maturation, DCs were washed 3 times, and 5 Â 10 5 PBMCs from cytomegalovirus (CMV) sera-positive donors were added to DCs. CMV sera-negative PBMCs were used as a control. Cells were incubated for 48 hours, then supernatant was analyzed by cytometric bead array (BD Biosciences) for IFNg. Cells were cultured for an additional 24 hours, stained with anti-CD8, HLA-A2 pp65(495-503) pentamer (ProImmune), and then stained intracellularly for IFNg.
Statistical analysis
Statistical comparisons were made by ANOVA, followed by posthoc comparisons using a 2-tailed t test. All tests were conducted with Prism 4 software (GraphPad Software, Inc.). Values of P < 0.05 were considered significant.
See Supplementary Material for additional materials and methods.
Results and Discussion
To compare tissue cultures to the primary tumor in situ, mRNA expression levels were profiled in replicate from 2 glioblastomas and cultured cells derived from the same tumor grown in 5% and 20% O 2 . There was a significant difference in the expression of 3,333 genes between the 20% O 2 culture and the in situ tumor in both patients ( Supplementary Fig. S1 ). Of these, 77 genes were differentially expressed between the 5% and 20% O 2 cultures (Fig. 1) , trending towards expression levels observed in situ in 5% O 2 cultures. Differential expression of CD133 (PROMININ-1) that was detected by microarray was further validated by PCR, flow cytometric, and Western blot analysis ( Fig. 2A-C C6orf15  DAPL1  OR11H12  LOC399898  BTN1A1  TEX15  C1orf32  SLC12A1  OSTbeta  DDIT4L  GSDMC  CABP1  C20orf46  HSPB7  FAM124A  GNA15  COL15A1  RASD2  GALNTL2  EDN1  PXDNL  STAC2  FMOD  SCNN1B  PCBP3  ADCY8  INHBB  LOC283174  RGS11  PROM1  HIF3A  ELAVL3  SORCS2  PGF  MYOM1  OXER1  COL4A4  STC1  MMP1  PNCK  AQP4  PHYHIPL  SPON1  EVI1  TRHDE  TRAF31P3  SEZ6L  TMEM35  SLC29A4  MATN4  ESPN  CLCNKB  PIWIL2  EPO  SLC22A3  PDE4C  DPRXP4  DLK2  C20orf200  SOST  TPSG1  CAPN12  GALIG  EFCAB3  FSCN2  C1orf188  GNG8  WNT10A  COL4A3  CLCNKA  FLJ14107 assessed for their ability to lyse the same HLA-A2 þ glioma cells that were used for priming. PBMCs primed by 5% O 2 TLs showed superior tumoricidal activity against glioma target cells cultured in standard 20% O 2 in 3 of 3 patients (Fig. 3A) . Blockade of MHC I-TCR interactions by pretreatment of target cells with an anti-MHC I antibody prevented specific lysis, implicating CTLs as the main effectors in this assay (Fig. 3B) . A plausible explanation for the enhancement in CTL priming would be improvement of DC maturation by 5% O 2 TLs. The expression of costimulatory and MHC molecules on DCs was measured after pulsing with TLs from 20% or 5% O 2 . There were no appreciable differences in expression of CD83, CD80, CD86, HLA-ABC, or HLA-DR (Supplementary Fig. S2 ). The levels of DC-elaborated IL-6, IL-8, IL-10, and IL-12p70 were measured 48 hours after lysate pulsing, revealing no significant differences between 5% and 20% O 2 lysates ( Supplementary  Fig. S3) . Therefore, the adjuvant activity of 5% O 2 TLs was not likely due to enhancing DC maturation or cytokine expression, suggesting other mechanisms.
We also interrogated the effect of oxygen on the target cells by establishing a competitive cytotoxicity assay whereby CTLs were cocultured with targets precultured in 5% and 20% O 2 . Target cells cultured in 5% O 2 were significantly more resistant to CTL killing than targets grown in 20% O 2 , only showing susceptibility to CTLs primed with TLs from 5% O 2 at high effector:target ratios (Fig. 3C) . We reproducibly observed suppression of the ability of CTLs primed by 20% O 2 TLs to kill any target in the presence of targets precultured in 5% O 2 (compare Fig. 3A-C) . We speculate that the target cells precultured in 5% O 2 may have expressed factors that inhibited CTL killing, which is supported by increased TGFb1/latentancy-associated peptide complex cell surface expression on a subset of target cells cultured in 5% O 2 ( Supplementary Fig. S4 ). The differences measured in target cell susceptibility to CTL killing were not due to differential labeling efficiency (Supplementary Fig. S5 ). Despite the ability of target cells grown in 5% O 2 to directly suppress CTL killing, when these cells were lysed and processed in DCs (wherein suppressive factors could be degraded or overridden), they reproducibly primed CTLs with enhanced ability to kill target cells at conventional and physiologic oxygen. Accordingly, CTLs primed by TLs from 5% O 2 would be expected to have more tumoricidal function in vivo where oxygen is limited.
Experiments were conducted to determine whether the superior CTL priming achieved with 5% O 2 TLs could be due to changes in lysate uptake. Immature DCs were pulsed with CFSE-labeled glioma TLs from cells grown in 5% compared with TLs derived in 20% O 2 (Fig. 4A) . Thus, as of yet unidentified factor(s) in the 5% O 2 TLs increased the fraction of DCs that engulfed TLs in tissue culture. We then tested the hypothesis that 5% O 2 TLs should exhibit intrinsic adjuvant properties independent of glioma antigen expression by mixing the lysates with pp65 derived from CMV. CMV-derived pp65 495-503 is an HLA-A2-restricted immunodominant epitope to which CMV sera-positive patients typically have CD8 T cell memory responses (reviewed in 24). PBMCs from sera-positive donors were cocultured with TL or TL/ pp65 495-503 loaded DCs. PBMCs from sera-negative donors were used to control for CD8 T cell activation independent of pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] . Soluble IFNg in the tissue culture supernatant was quantified as a measure of CD8 T cell activation (Fig. 4B) . There was no significant difference in IFNg elaborated between the nonpulsed and TL-pulsed PBMCs from serapositive donors, showing negligible reactivity to possible CMV antigens in the TLs themselves (25) . As expected, PBMCs from sera-positive donors primed with pp65 495-503 alone (no TLs) elaborated IFNg at levels 10-fold above background, whereas sera-negative donor PBMCs did not respond to pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] . PBMCs primed with pp65 495-503 mixed with 5% O 2 TLs (17) . In summary, our data show that within tissue culture oxygen functions as a master "immunologic switch" by simultaneously regulating the expression of glioma antigens and factors that modulate DC-mediated priming of CD8 T cells. Growing primary glioma cells in 1% to 7% O 2 increased cancer stem cell markers in several previous studies (13) (14) (15) and this study, suggesting that the T cells primed might be better suited to eradicate cancer stem cells in situ. By selecting for expression of glioma antigens that are more abundant on the tumor in situ, we propose that oxygen can be exploited to prime CD8 T cells with greater specificity to antigens that are actually presented MHC molecules in situ.
Most of the experiments conducted were done by reverting cultures initially grown in 20% O 2 to 5% O 2 , suggesting that the immunogenicity of standard tumor cell vaccines could be "rescued" by conversion to 5% O 2. However, the enhancement in immunogenicity afforded by low oxygen was not an artifact of conversion from 20% O 2 to 5% O 2 because cells cultured directly from surgical resections in 5% O 2 exhibited, (i) increased expression of CD133, IL-13Ra2, and Epha2 (Supplementary Fig. S6 ) and (ii) enhanced uptake by DCs (Fig. 4A) , and intrinsic adjuvant activity as shown by increasing pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] cross-priming (Fig. 4B-C) . The same trends in Fig. 4 were also observed by reverting cultures initially grown in 20% O 2 to 5% O 2 (data not shown). Thus, the changes in immunogenicity are reversible and are present regardless of the initial oxygen tension used to establish the cell culture. Tumor cells grown in physiologic oxygen are inherently more capable of priming CD8 T cells by a mechanism that seems independent of increasing MHC I/II, CD80/83/86, IL-6, IL-8, IL-10, or IL12p70 expression in DCs. A deeper investigation into the mechanisms by which oxygen regulates tumor cell immunogenicity in the context of T cell priming needs to be undertaken to establish a molecular basis for our results. We propose that vaccines made by expansion of primary tumor cells in physiologic oxygen will serve as a powerful system to induce clinically useful antitumor immune responses.
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